Vemurafenib in patients with BRAF (V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a nonrandomized, multicenter, open-label, Phase II trial (NCT01286753). This evidence concerns the gene BRAF and thyroid gland papillary carcinoma.